- Home
- UTHR vs MRNA Comparison
UTHR vs MRNA Comparison
Compare UTHR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- MRNA
- Stock Information
- Founded
- UTHR 1996
- MRNA 2010
- Country
- UTHR United States
- MRNA United States
- Employees
- UTHR N/A
- MRNA N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UTHR Health Care
- MRNA Health Care
- Exchange
- UTHR Nasdaq
- MRNA Nasdaq
- Market Cap
- UTHR 16.2B
- MRNA 16.5B
- IPO Year
- UTHR 1999
- MRNA 2018
- Fundamental
- Price
- UTHR $359.23
- MRNA $39.39
- Analyst Decision
- UTHR Buy
- MRNA Hold
- Analyst Count
- UTHR 14
- MRNA 19
- Target Price
- UTHR $370.86
- MRNA $79.50
- AVG Volume (30 Days)
- UTHR 313.6K
- MRNA 9.0M
- Earning Date
- UTHR 02-19-2025
- MRNA 02-20-2025
- Dividend Yield
- UTHR N/A
- MRNA N/A
- EPS Growth
- UTHR 25.10
- MRNA N/A
- EPS
- UTHR 22.72
- MRNA N/A
- Revenue
- UTHR $2,756,200,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- UTHR $26.32
- MRNA N/A
- Revenue Next Year
- UTHR $10.37
- MRNA N/A
- P/E Ratio
- UTHR $15.82
- MRNA N/A
- Revenue Growth
- UTHR 25.04
- MRNA N/A
- 52 Week Low
- UTHR $208.62
- MRNA $35.80
- 52 Week High
- UTHR $417.82
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- UTHR 43.90
- MRNA 39.16
- Support Level
- UTHR $358.82
- MRNA $37.44
- Resistance Level
- UTHR $383.00
- MRNA $44.38
- Average True Range (ATR)
- UTHR 9.97
- MRNA 2.57
- MACD
- UTHR -0.80
- MRNA 0.06
- Stochastic Oscillator
- UTHR 29.51
- MRNA 19.55
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.